MedWatch

GN Hearing restructures after research and development letdown

The year of 2021 was meant to bring two new product launches from hearing aid manufacturer GN Hearing, but its research and development division hasn't delivered. Subsequently, the company has dismissed its head of R&D and downgraded its guidances markedly, says CEO at GN Hearing.

Gitte Aabo, CEO at GN Hearing | Photo: GN Hearing / PR

When employees can't deliver as promised, actions must be taken.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs